Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.

Journal of molecular graphics & modelling - 1 Sept 2010

Soares Rosemberg O, Batista Paulo R, Costa Mauricio G S, Dardenne Laurent E, Pascutti Pedro G, Soares Marcelo A

Abstract excerpt

A major concern in the antiretroviral (ARV) treatment of HIV infections with protease inhibitors (PI) is the emergence of resistance, which results from the selection of distinct mutations within the viral protease (PR) gene. Among patients who do not respond to treatment with the PI nelfinavir (NFV), the D30N mutation is often observed. However, several reports have shown that D30N emerges with different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV Protease
Share to HIV Protease Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen Bonding

Share to Hydrophobic and Hydrophilic Interactions

Share to Molecular Dynamics Simulation

Share to Nelfinavir

Share to Surface Properties

Share to Thermodynamics

Source

Identifiers

PMID: 20541446
DOI: 10.1016/j.jmgm.2010.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.PMID 20541446Read ↗

New Insights into the In Silico Prediction of HIV Protease Resistance to NelfinavirSemantic proximity Read ↗

Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.Semantic proximity Read ↗

Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.Semantic proximity Read ↗

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.Semantic proximity Read ↗

Integrative Computational Approaches for Understanding Drug Resistance in HIV-1 Protease Subtype CSemantic proximity Read ↗

Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.Semantic proximity Read ↗

Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.Semantic proximity Read ↗

Molecular Basis for Reduced Cleavage Activity and Drug Resistance in D30N HIV-1 proteaseSemantic proximity Read ↗

Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.Semantic proximity Read ↗

Drug resistance mechanisms of three mutations V32I, I47V and V82I in HIV-1 protease toward inhibitors probed by molecular dynamics simulations and binding free energy predictionsSemantic proximity Read ↗

The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.Semantic proximity Read ↗

Multiple Molecular Dynamics Simulations of the Inhibitor GRL-02031 Complex with Wild Type and Mutant HIV-1 Protease Reveal the Binding and Drug-Resistance Mechanism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.